Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 40
Why patients stop GLP-1 drugs, and restart
A narrative review in Diabetes, Obesity & Metabolism examines GLP-1 RA discontinuation rates, reasons, and weight-regain patterns after stopping.
GLP-1 drugs and severe GI motility risk
A 626,000-person cohort study found GLP-1 therapies carry a 37% higher relative risk of severe GI events versus SGLT-2 inhibitors.
Tirzepatide and ketoacidosis: FAERS signal
A FAERS analysis flags starvation ketoacidosis as a post-marketing signal for tirzepatide. Here is what the numbers say.
Tirzepatide and MASLD: a mouse study
A mouse study ties tirzepatide's liver effect in MASLD to the CCL2/CCR2 axis, adding mechanistic detail to SYNERGY-NASH.
Tirzepatide in Smith-Magenis syndrome
A JCEM case report found 9.4% weight loss and reduced aggression in a patient with Smith-Magenis syndrome on tirzepatide 5 mg weekly.
Tirzepatide after bariatric surgery
An Italian study reports 18.1% weight loss at 24 weeks in 34 post-bariatric patients on tirzepatide. Early data, small sample.
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.
GLP-1 drugs and fewer knee replacements
A database study of over 42,000 patients links GLP-1 receptor agonist use to significantly lower rates of knee replacement surgery.
Semaglutide lifts lymphatic pump in mice
A 2026 mouse study found GLP-1 receptors concentrated in lymphatic endothelial cells. Semaglutide activation improved vessel pumping capacity.
SURPASS-CVOT and the GLP-1 ceiling question
A JACC commentary asks why tirzepatide beat dulaglutide on metabolism but not on MACE in SURPASS-CVOT, and what GIP receptor activation adds beyond GLP-1.
Tirzepatide CV biomarkers in SURMOUNT-1
A SURMOUNT-1 post hoc analysis found tirzepatide reduced CRP, IL-6, leptin, and PAI-1 at 72 weeks. What the biomarker shifts mean, and what they do not.
15-PGDH and muscle loss on GLP-1 drugs
A Stanford mouse study finds that inhibiting 15-PGDH preserved muscle repair during semaglutide weight loss without reducing fat loss.